Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07429006

SAD and MAD Study of AKB-9090 in Healthy Adult Participants

This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with five dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with three dose cohorts. Approximately 40 participants in SAD and 30 in MAD are planned to be enrolled.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Investigator Site #1

Auckland, New Zealand

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Healthy adult participants with no clinically significant findings, as judged by the investigator, based on physical examination, 12-lead ECG, alcohol breath test, and clinical laboratory tests (including serum chemistry, hematology, coagulation, urine drug screen, and urinalysis).
  • Body mass index (BMI) greater than 18.5 and less than 32.0 kg/m^2 at screening.
  • In the Investigator's opinion, willing and able to provide written informed consent and comply with the all protocol requirements, including required confinement, outpatient visits, and protocol-specified restrictions (including refraining from major lifestyle changes) from signature of the informed consent form (ICF) through the last study visit.

Key Exclusion Criteria:

  • Clinically significant metabolic, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatologic, urogenital, ophthalmologic, ear/nose/throat, psychiatric, or neurologic disorder.
  • History of active or recurrent malignancy within 2 years before screening or during the screening period, or currently receiving treatment or suppressive therapy for cancer, except for:
  • Treated basal cell carcinoma of the skin
  • Curatively resected squamous cell carcinoma of the skin
  • Treated colonic or cervical carcinoma in situ
  • Abnormal ECG findings at screening, including:
  • Severe bradycardia (heart rate <40 beats per minute) on any measurement
  • Mean QT Interval Using Fridericia's Formula (QTcF) >450 msec for males or >470 msec for females
  • Elevated laboratory values (>1.25 × upper limit of normal [ULN]) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), or creatinine at the screening visit or at check-in.
  • Evidence of acute or chronic hepatitis B (positive hepatitis B surface antigen) or hepatitis C infection (positive hepatitis C antibody and positive hepatitis C ribonucleic acid [RNA] test).
  • Use of nicotine-containing products (including cigarettes, cigars, tobacco, gum, patches, vaping, and e-cigarettes), caffeine-containing foods or beverages, and alcohol-containing foods or beverages during study.

Treatment and study plan

AKB-9090

Drug

AKB-9090 will be administered intravenously

Placebo

Other

Matching Placebo administered intravenously

Primary outcomes

  1. Number of participants who will report serious Treatment emergent adverse events (TEAEs) and TEAEs

    Time frame: From First Dose to Day 7

  2. Number of Participants with Clinically Significant Changes in Physical Examinations

    Time frame: From First Dose to Day 7

  3. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: From First Dose to Day 7

  4. Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG)

    Time frame: From First Dose to Day 7

  5. Number of Participants with Clinically Significant Changes in Chemistry parameters

    Time frame: From First Dose to Day 7

  6. Number of Participants with Clinically Significant Changes in Hematology Parameters

    Time frame: from first dose to Day 7

  7. Number of Participants with Clinically Significant Changes in Lipid Parameters

    Time frame: From First Dose to Day 7

  8. Number of Participants with Clinically Significant Changes in Coagulation Parameters

    Time frame: From First Dose to Day 7

  9. Number of Participants with Clinically Significant Changes in Urinalysis Parameters

    Time frame: From First Dose to Day 7

Secondary outcomes

  1. Stage 1 SAD Cohorts: Maximum observed plasma concentration (Cmax) of AKB-9090

    Time frame: At Day 1

  2. Stage 1 SAD Cohorts: Time of maximum plasma concentration (Tmax) of AKB-9090

    Time frame: At Day 1

  3. Stage 1 SAD Cohorts: Area under concentration time curve (AUC) from time 0 to the last observation (AUClast) of AKB-9090

    Time frame: At Day 1

  4. Stage 1 SAD Cohorts: Apparent body clearance (CL) of AKB-9090

    Time frame: At Day 1

  5. Stage 1 SAD Cohorts: AUC from time 0 to infinity (AUCinf) of AKB-9090

    Time frame: At Day 1

  6. Stage 1 SAD Cohorts: Terminal half-life (T1/2) of AKB-9090

    Time frame: At Day 1

  7. Stage 2 MAD Cohorts: Cmax of AKB-9090

    Time frame: At Day 1 and Day 7

  8. Stage 2 MAD Cohorts: Tmax of AKB-9090

    Time frame: At Day 1 and Day 7

  9. Stage 2 MAD Cohorts: AUC to 24 hours post-dose (AUC24) of AKB-9090

    Time frame: At Day 1

  10. Stage 2 MAD Cohorts: CL of AKB-9090

    Time frame: At Day 1 and Day 7

  11. Stage 2 MAD Cohorts: T1/2 of AKB-9090

    Time frame: At Day 1 and Day 7

  12. Stage 2 MAD Cohorts: AUC at Steady state (AUCss) of AKB-9090

    Time frame: At Day 7

  13. Stage 1 SAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Erythropoietin (EPO)

    Time frame: Baseline (Day 1) and at 6, 12, 18, and 24 hours post-dose

  14. Stage 1 SAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Red Blood Cell Count (RBC)

    Time frame: Baseline (Day 1) and At Day 2

  15. Stage 1 SAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Reticulocyte Count

    Time frame: Baseline (Day 1) and At Day 2

  16. Stage 2 MAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - EPO

    Time frame: Baseline (Day 1 and Day 7) and at 6, 12, 18, and 24 hours post-dose

  17. Stage 2 MAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - RBC

    Time frame: Baseline (Day 1) and At Days 4 and 8

  18. Stage 2 MAD Cohorts: Change from Baseline in Pharmacodynamic Biomarker - Reticulocyte Count

    Time frame: Baseline (Day 1) and At Days 4 and 8

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Leanne Barnett

CONTACT

[email protected]

+64 9 373 3474

Sponsors and collaborators

Lead sponsor

Akebia Therapeutics

Industry

Collaborators

  • Emerald Clinical Trials

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Single (SAD) and Multiple Ascending-Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AKB-9090 Administered Intravenously to Healthy Adult Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 24, 2026
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.